LumiraDx Ltd
DelistedCIK 1685428fmd_0GX1S5P2XXM23AQVN1QR8GBGBJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2023, 7 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Total revenues | 23 | 139 | 421 | 254 |
| Cost of revenue | 14 | 86 | 270 | 290 |
| Gross profit | 9 | 53 | 152 | (35) |
| Research and development | 87 | 108 | 130 | 142 |
| Selling, general and administrative | 37 | 46 | 131 | 145 |
| Operating income | (115) | (101) | (145) | (321) |
| Interest expense | 39 | 173 | 118 | 136 |
| Income before taxes | (143) | (251) | (98) | (443) |
| Income tax expense | (10) | (10) | 3 | 4 |
| Net income from continuing operations | (133) | (241) | (101) | (448) |
| Net income | (133) | (241) | (101) | (448) |
| Net income to common shareholders | (133) | (241) | (101) | (448) |